Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Galectin-1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Galectin-1 is a protein that in humans is encoded by the LGALS1 gene.
Neuronal growth factor galectin-1
InactiveUS6890531B1Peptide/protein ingredientsAntibody mimetics/scaffoldsNerve degenerationADAMTS Proteins
This invention relates to a remedy for neuropathy, such as nerve injury, nerve degeneration, and hypofunction upon nerve grafting, which contains as the active ingredient galectin-1 having an amino acid sequence represented by SEQ ID NO:1 or its derivative; a protein having the amino acid sequence represented by SEQ ID NO:1 or one having a homology of 90% or more at the amino acid level with the sequence of SEQ ID NO:1 and carrying a disulfide bond(s) at least between Cys at the 16-position (Cys 16) and Cys at the 88-position (Cys 88) among cystein residues at the 2-position (Cys 2), 16-position (Cys 16), 42-position (Cys 42), 60-position (Cys 60), 88-position (Cys 88) and 130-position (Cys 130); and a process for producing the galectin-1 or its derivative protein by using an affinity column having an antibody to the above protein.
Owner:KIRIN BREWERY CO LTD
Method for recombinant protein production in mammalian cells
Some embodiments relate to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an sh RNA or an si RNA directed against the Galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising an shRNA or an si RNA and a CHO cell.
Owner:UNIVERSITY OF BIELEFELD
Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
Owner:DANA FARBER CANCER INST INC +2
Compositions and uses of a galectin for treatment of dry eye syndrome
Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and / or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active agent which is a galectin-1 protein, a galectin-3 protein, galectin-7 protein and / or a galectin-8 protein, and a suitable carrier or a diluent, are provided.
Owner:TRUSTEES OF TUFTS COLLEGE
Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer
InactiveUS7964575B2Dramatic efficacyReduce expressionSugar derivativesGenetic material ingredientsMelanomaRadical radiotherapy
The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and / or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and / or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and / or gene therapy.
Owner:UNIV LIBRE DE BRUXELIES +1
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
ActiveUS8968740B2Extensive remodelingIncreased influx and expansionPeptide/protein ingredientsImmunoglobulins against growth factorsLymphoproliferative diseasePost transplant
Owner:DANA FARBER CANCER INST INC +3
Colorectal cancer marker galectin, method for analyzing galectin concentration in blood sample, and kit for detecting colorectal cancer marker galectin
InactiveUS20130065258A1High positive rateImprove patient capture rateBiological material analysisPeptide preparation methodsGalectin-3 AntibodyPrognostic prediction
The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.
Owner:SHIMADZU CORP +1
Compositions and uses of a galectin for treatment of dry eye syndrome
ActiveUS20060189514A1Good effectImprove integritySenses disorderPeptide/protein ingredientsActive agentGalectin-1
Owner:TRUSTEES OF TUFTS COLLEGE TUFTS UNIV
Tumor markers for ovarian cancer diagnosis
The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.
Owner:NAT TAIWAN UNIV
Biological probe used for detecting tumour marker galectin-1 and preparation method thereof
InactiveCN105158467ASpecial spatial anisotropyResponsiveMaterial analysisResponse effectGal galnac lectin
The invention provides a biological probe used for detecting tumour marker galectin-1, and the biological probe is a compound formed by connecting sulfhydryl-containing lactose with a gold nanorod via a gold-sulfur bond. The sulfhydryl-containing lactose is firstly used for modifying the gold nanorod, the sulfhydryl-containing lactose is connected with the gold nanorod via the gold-sulfur bond, and the combination capability is strong. The gold nanorod is loaded with the carbohydrate micromolecule lactose and is subjected to stable specific modification, the lactose part in the obtained probe possesses specific recognition effect on galectin-1, and additionally because of the precise optical response effect of the gold nanorod, finally the biological probe is capable of efficiently specifically detecting galectin-1. Furthermore, the invention also provides a preparation method for the biological probe used for detecting the tumour marker galectin-1, and the preparation method for the biological probe is simple and practicable, mild in conditions and relatively low in cost.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Method and composition of inducing hair follicle neogenesis
The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. The composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I.
Owner:NAT TAIWAN UNIV +1
Activator of signal transduction pathway
The present invention is directed to providing the activator of the integrin signaling in neural stem cells or neural progenitors and the method for using the same. The activator of the integrin signaling comprises galectin-1 and can be used as a regulator that regulates maintenance, survival, or differentiation of a neural stem cells or a neural progenitor.
Owner:KEIO UNIV
Application of membranin Annexin A2 of cell Thp-1 in Ac-Gal-1 induced apoptosis
ActiveCN109306368AThe verification method is simpleEasy to operateMicrobiological testing/measurementBiological testingApoptosisGalectin-1
The invention relates to application of membranin Annexin A2 of a cell Thp-1 in Angiostrongylus Cantonensis (Ac) protein Galectin-1 induced apoptosis. According to the application of the membranin Annexin A2 of the cell Thp-1 in Ac protein Galectin-1 induced apoptosis, the application provides a theoretical basis for researching applications of a pathogenesis mechanism and control of Ac and treatment of angiostrongyliasis cantonensis and provides a potential acting target, i.e., the Annexin A2 for research and development of treatment drugs; meanwhile, a foundation for research and developmentof angiostrongyliasis cantonensis treatment drugs is laid, and a target is provided for customized treatment of the Ac, so that the application has considerable market prospect and applicability.
Owner:WENZHOU MEDICAL UNIV
Compositions, kits, and methods for the modulation of immune responses using galectin-1
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
Owner:DANA FARBER CANCER INST INC +2
Application of Angiostrongylus Cantonensis protein Galectin-1
ActiveCN106546753AUnderstand the mechanism of diseaseThe verification method is simpleBiological material analysisBiological testingMedicineGalectin-1
The invention relates to an application of Angiostrongylus Cantonensis protein Galectin-1. The application is an immunosuppression effect application the Angiostrongylus Cantonensis protein Galectin-1, and especially is an application of the Angiostrongylus Cantonensis protein Galectin-1 in the preparation of medicines with an immunosuppression effect. The Angiostrongylus Cantonensis protein Galectin-1 provides theoretic basis for treatment of Angiostrongylus cantonensis, provides potential action target for development of treatment medicines, lays foundation for the development of the Angiostrongylus cantonensis treatment medicines, provides target for customized treatment of Angiostrongylus Cantonensis, and has good market prospect and applicability.
Owner:WENZHOU MEDICAL UNIV
Galectin-1 (GAL1) as a biomarker for differential diagnosis of osteosarcoma and chondrosarcoma
InactiveUS20120028825A1Microbiological testing/measurementLibrary screeningMyxoid chondrosarcomaGalectin-1
The present invention relates to a method for differential diagnosis of osteosarcoma and chondrosarcoma, especially chondroblastic osteosarcoma and conventional chondrosarcoma, in a patient comprising a step consisting of detecting galectin-1 (GAL1) expression in a bone sample obtained from said patient.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Recombinant galactose agglutinin-1 two-string protein and preparation method thereof
InactiveCN101830975AEasy to separate and purifyInexpensive separation and purification processPeptide preparation methodsFermentationChromatographic separationProkaryotic expression
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Tumor Marker For Ovarian Cancer Diagnosis
InactiveUS20090098595A1Accurate detectionMicrobiological testing/measurementPeptide preparation methodsCathepsin BOvarian tissue
The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.
Owner:NAT TAIWAN UNIV
Reagent kit for detecting 2-diabetes serum mark in Chinese people
The invention relates to the reagent box to detect new serum of II-type diabetes. Specially, it applies the serum of galectin-1 and corresponding express-level in patient to modify the box. It also relates to the application in diagnosis and treatment of galectin-1.
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Immune Disorders Using Galectin-1
ActiveUS20090176223A1Reduced expression levelHigh expressionMicrobiological testing/measurementAntibody ingredientsAnaplastic CellGalectin-1
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
Owner:DANA FARBER CANCER INST INC +2
Method for expressing soluble angiostrongylus cantonensis galectin-1 protein by using pCold carrier
InactiveCN104593401AWide variety of sourcesReduce expressionPeptide preparation methodsFermentationSolubilityPurification methods
The invention relates to a method for expressing a soluble angiostrongylus cantonensis galectin-1 protein by using a pCold carrier. The method comprises the following steps: (1) synthesizing a primer; (2) amplifying galectin-1 genes; (3) building galectin-1 recombinant plasmids; (4) performing inducible expression and purification on the recombinant fusion protein Galectin-1 to obtain the soluble angiostrongylus cantonensis galectin-1 protein. The method is simple and easy to operate, wide in sources of used raw materials and low in cost; an expression purification method for performing inducible expression on the soluble angiostrongylus cantonensis galectin-1 protein under low temperature is built, the expression of a escherichia coli protein is reduced, the purification efficiency of a target protein is improved, and the biology activity of the galectin-1 protein is also guaranteed. The galectin-1 protein prepared by using the method is high in solubility and lays a foundation for wide application of the galectin-1 protein.
Owner:WENZHOU MEDICAL UNIV
Application of kaempferol to drugs for treating osteoarthritis
InactiveCN109453160AAlleviate the degeneration of articular cartilageAlleviate joint space narrowingOrganic active ingredientsSkeletal disorderSensory neuronNerve cells
The invention discloses application of kaempferol to drugs for treating osteoarthritis. Kaempferol decreases expression of anti-galectin-1 in sensory neurone by inhibiting NF-kappa B and MAPK signal pathway activated in the inflammatory environment, reducing expression of c-Fos, c-Jun and delta FosB in sensory neurone and inhibiting combination activity of transcription factor activator protein-1(AP-1) and DNA, expression of anti-galectin-1 in nerve cell is reduced, and accordingly development of osteoarthritis is relieved. The invention provides a new drug for clinic treatment of osteoarthritis, and meanwhile states the mechanism of the novel treatment drug. New thought and experiences are provided for better understanding the pathological process of osteoarthritis and developing the drugs for treating osteoarthritis in the future.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Composition for preventing or treating keloid or hypertrophic scar
PendingCN112839664AOrganic active ingredientsCompound screeningEukaryotic initiation factorThioredoxin
The present invention relates to a pharmaceutical composition for preventing or treating a hypertrophic scar. The present inventors acknowledged that expression inhibition of thioredoxin 5, PRRC1, S100A11, galectin 1, filamin A, eukaryotic initiation factor-5A, annexin A2 and fatty acid binding proteins 5 can be a new target for relieving and treating a hypertrophic scar. According to the present invention, the treatability of a hypertrophic scar is confirmed by producing thioredoxin 5-, PRRC1-, S100A11-, galectin 1-, filamin A-, eukaryotic initiation factor-5A-, annexin A2- and FABP5-specific siRNAs. Therefore, the knockdown of the proteins or genes coding same induces cell death in a hypertrophic scar and reduces collagen expression and thus can be highly useful for scar treatment.
Owner:TEGO SCI
Gigaxonin fusion protein and methods for treating giant axonal neuropathy
ActiveUS20140336128A1Reduce aggregationPolypeptide with localisation/targeting motifNervous disorderPhosphorylationGalectin-1
The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.
Owner:INDIANA UNIV RES & TECH CORP
Alpha-d-galactoside inhibitors of galectins
ActiveUS20190225638A1High affinityHigh selectivityAntibacterial agentsSenses disorderDiseaseGalectin-1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.
Owner:GALECTO BIOTECH
Treatment of central nervous tumours
ActiveUS20180344658A1Efficient transportReduce expressionPowder deliveryOrganic active ingredientsGlioblastomaNanoparticle
The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).
Owner:UNIV LIBRE DE BRUXELIES +1
Method of detecting galectin-1 in blood and reagent therefor
ActiveCN105241872AAvoid detectionHave clinical valueMaterial analysis by observing effect on chemical indicatorColor/spectral properties measurementsCancer metastasisMolecular level
The invention provides a method of detecting galectin-1 in to-be-tested samples, especially in blood, and a reagent therefor. The method includes the steps of: contacting and mixing gold nano rods, which is modified by lactose, as a probe with the to-be-tested sample; maintaining the system temperature at 20-37 DEG C; allowing the system to stand for 10-120 min; and detecting the galectin-1 by observing the color of the mixture system. In the invention, with the gold nano rods modified by lactose (Lac-GNRs) as the probe and ultraviolet-visible light-near infrared spectrophotometer as detection method, high-effective and specific detection to the galectin-1 is carried out at the molecular and cellular levels. The method can accurately detect the galectin-1 in human blood and is an effective method of monitoring early stage of cancer metastasis.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Composition for preventing or treating keloids or hypertrophic scars
InactiveUS20210388352A1Accurate diagnosisInhibits expression activityOrganic active ingredientsCompound screeningKeloidGalectin-1
The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
Owner:TEGO SCI
Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing gal1
InactiveUS20160215052A1Avoid delayVertebrate antigen ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsEpitopeMonoclonal antibody
Owner:DANA FARBER CANCER INST INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com